0000000001051580

AUTHOR

R. Labianca

showing 7 related works from this author

391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials

2021

Oncologymedicine.medical_specialtybusiness.industryColorectal cancerHematologymedicine.diseaseOutcome (game theory)Adjuvant TrialsMetforminPooled analysisOncologyInternal medicineDiabetes mellitusmedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated w…

2002

Background: K-ras mutations, one of the earliest events observed in colorectal carcinogenesis, are mostly found in codons 12 and 13, and less frequently in codon 61, all three of which are estimated to be critical for the biological activity of the protein. Nevertheless the prognostic significance of such mutations remains controversial. Our purpose was to assess whether any or specific K-ras mutations in primary colorectal cancer had prognostic significance and were linked to clinico-pathological parameters. Patients and methods: Paired tumor and normal tissue samples from a consecutive series of 160 untreated patients (median of follow up 71 months), undergoing resective surgery for prima…

MaleSettore MED/06 - Oncologia MedicaColorectal cancermedicine.disease_causePolymerase Chain ReactionMetastasisProspective StudiesMutationTransition (genetics)Biopsy NeedleDNA NeoplasmHematologyMiddle AgedFlow CytometryPrognosisColorectal carcinomaOncologyFemaleColorectal NeoplasmsAdultGenetic Markersmedicine.medical_specialtyK-ras mutationAdenocarcinomaSensitivity and SpecificityPredictive Value of TestsCulture TechniquesInternal medicineCarcinomamedicineHumansCodonGeneAgedNeoplasm StagingProbabilityProportional Hazards ModelsAnalysis of VarianceProportional hazards modelbusiness.industrymedicine.diseaseDNA ploidyGenes rasLogistic ModelsEndocrinologyGenetic markerMultivariate AnalysisMutationCancer researchbusinessAnnals of Oncology
researchProduct

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, B…

2013

Oncologymedicine.medical_specialtybusiness.industryFOLFIRINOXHematologymedicine.diseaseGastroenterologyGemcitabineOncologyPancreatic Cancer Stage IVPancreatic cancerInternal medicineMetastatic pancreatic cancermedicineGastrointestinal cancerbusinessmedicine.drugNab-paclitaxel
researchProduct

Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013

MaleOncologyOrganoplatinum CompoundsOxaloacetatesColorectal cancerLeucovorinColonoscopyChromosome DisordersDeoxycytidineRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsIntestinal MucosaSigmoidoscopyEarly Detection of Cancermedicine.diagnostic_testFollow up studiesColonoscopyHematologyEuropeClinical PracticeTreatment OutcomeOncologyDiagnosis treatmentChemotherapy AdjuvantLymphatic MetastasisOccult BloodColonic NeoplasmsFemaleFluorouracilChromosome Deletionmedicine.drugRiskmedicine.medical_specialtyAntineoplastic AgentsRisk AssessmentCapecitabineInternal medicinemedicineHumansCapecitabineNeoplasm Stagingbusiness.industryGeneral surgeryCancerSigmoidoscopymedicine.diseaseCarcinoembryonic AntigenNeoplasm Recurrence LocalChromosomes Human Pair 18businessFollow-Up StudiesAnnals of Oncology
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, B…

2011

Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics on the diagnosis and management of patients with gastric cancer. This article summarizes the recommendations and expert opinion on gastric cancer. It discusses and reflects on the regional differences in the incidence and care of gastric cancer, the definition of gastro-esophageal junction and its implication for treatment strategies and presents the latest recommendations in the staging and treatment of primary and metastatic gastric cancer. Recognition is given to the ne…

Continuous infusionComputer assisted radiotherapyFolic acidFluorodeoxyglucose f 18Gimeracil plus oteracil potassium plus tegafurInfection controlIntensity modulated radiation therapyDocetaxelCancer stagingMetastatic gastric cancerRisk FactorsPrevalenceDrug fatalityOverall survivalNeoplasm MetastasisPriority journalddc:616Conference paperdigestive oral and skin physiologyFolinic acidHematologyPrognosisOxaliplatinNuclear magnetic resonance imagingBevacizumabSurvival RateOncologyCyanocobalaminPractice Guidelines as TopicDrug dose reductionFluorouracilEsophageal adenocarcinomaHumanPositron emission tomographymedicine.medical_specialtyNeutropeniaStomach cancerStomach neoplasmsMEDLINESide effectStomach adenocarcinomaPatient careIrinotecanHelicobacter infectionPrimary tumorEndoscopic echographyAdvanced cancerEndoscopic mucosal resectionComputer assisted tomographyStomach Neoplasms/*diagnosis/pathology/*therapymedicineHumansGenetic Predisposition to DiseaseGastrointestinal cancerPhase 3 clinical trial (topic)Intensive care medicineSurvival ratePlaceboCapecitabineEpirubicinCa 19-9 antigenStomach Neoplasms/diagnosis/pathology/therapyHelicobacter pyloribusiness.industryCancerTrastuzumabCardiovascular riskmedicine.diseaseCancer susceptibilitydigestive system diseasesSurgeryClinical trialMetastasis potentialExpert opinionMeta analysis (topic)Cancer adjuvant therapyCarcinoembryonic antigenLower esophagus sphincterCisplatinCaloric intakebusinessCancer incidenceRegional differencesAnnals of Oncology
researchProduct

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/Wo…

2010

The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC. 21 Suppl 6 vi1 10

OncologyColorectal cancermedicine.medical_treatmentBraf proteinGastroenterologyMetastasisDrug antagonismTargeted therapyMetastasisAntineoplastic agentsPathologyConference paperBiological markersPredictive markerHematologyPrognosisChemotherapy regimenAntineoplastic agentOncologyProto-oncogene proteinsRas proteinHumanReceptormedicine.medical_specialtyNeoplasm metastasisRas proteinsMEDLINEOncoproteinColorectal neoplasmsProto-oncogene proteins b-rafInternal medicineGeneticsmedicineHumansGastrointestinal cancerColorectal tumorB raf kinaseEpidermal growth factor receptorKras proteinbusiness.industryEpidermal growth factorCancermedicine.diseasedigestive system diseasesBiological markerMetabolismSpainMutationCarcinoembryonic antigenMicrosatellite instabilitybusinessAnnals of Oncology
researchProduct